
Quarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Revenue 2011-2026 | INFU
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 M | 102 M | 97.4 M | 81.1 M | 67.1 M | 71.1 M | 70.5 M | 72.1 M | 66.5 M | 62.3 M | 58.8 M | 54.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 M | 54.6 M | 76.2 M |
Quarterly Revenue InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.5 M | 36 M | 34.7 M | - | 35.3 M | 33.7 M | 32 M | - | 31.9 M | 31.7 M | 30.4 M | - | 27.3 M | 27 M | 26.8 M | - | 26.6 M | 24.8 M | 24.5 M | - | 25.1 M | 26 M | 21.6 M | - | 21.5 M | 19.7 M | 18.2 M | - | 16.7 M | 16.4 M | 16.5 M | - | 17.6 M | 16.9 M | 17.7 M | - | 17.2 M | 18.1 M | 18.3 M | 18.7 M | 18.3 M | 16.9 M | 16.7 M | - | 16.6 M | 16.4 M | 17.2 M | - | 15.7 M | 14.7 M | 14.7 M | - | 14.2 M | 14.1 M | 14.3 M | - | 14.5 M | 13.1 M | 13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.5 M | 13 M | 21.6 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
10.4 B | $ 75.4 | -0.8 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
12.8 M | $ 11.21 | -1.41 % | $ 27.2 M | ||
|
The Cooper Companies
COO
|
4.09 B | $ 63.09 | -1.94 % | $ 12.6 B | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
2.23 B | $ 121.01 | -1.5 % | $ 2.98 B | ||
|
iRhythm Technologies
IRTC
|
747 M | $ 125.44 | -0.41 % | $ 4.01 B | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 59.84 | -1.06 % | $ 3.01 B | ||
|
electroCore
ECOR
|
32 M | $ 6.15 | 1.32 % | $ 52.2 K | ||
|
Repro Med Systems
KRMD
|
41.1 M | $ 4.08 | 0.49 % | $ 188 M | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
10.1 B | $ 466.64 | -0.92 % | $ 167 B | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.1 | -3.23 % | $ 96.2 M | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 119.63 | -2.0 % | $ 5.79 B | ||
|
Milestone Scientific
MLSS
|
8.97 M | $ 0.33 | -4.15 % | $ 27.1 M | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 178.51 | -0.08 % | $ 9.51 B | ||
|
Merit Medical Systems
MMSI
|
1.52 B | $ 66.74 | -1.02 % | $ 3.95 B | ||
|
Envista Holdings Corporation
NVST
|
2.72 B | $ 26.49 | -1.05 % | $ 4.45 B | ||
|
Pulse Biosciences
PLSE
|
350 K | $ 21.83 | -3.62 % | $ 1.47 B | ||
|
Retractable Technologies
RVP
|
38.3 M | $ 0.62 | -2.99 % | $ 18.6 M | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 51.51 | -0.87 % | $ 169 M | ||
|
LeMaitre Vascular
LMAT
|
250 M | $ 112.4 | -1.85 % | $ 2.54 B | ||
|
STAAR Surgical Company
STAA
|
239 M | $ 26.7 | 0.07 % | $ 1.32 B | ||
|
STERIS plc
STE
|
5.46 B | $ 219.75 | -1.1 % | $ 21.7 B | ||
|
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | ||
|
Teleflex Incorporated
TFX
|
569 M | $ 135.52 | 0.33 % | $ 6.05 B | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 20.9 | -2.38 % | $ 963 M | ||
|
Stereotaxis
STXS
|
32.4 M | $ 1.86 | -3.63 % | $ 169 M | ||
|
Baxter International
BAX
|
11.2 B | $ 17.94 | -2.97 % | $ 9.2 B | ||
|
ResMed
RMD
|
3.58 B | $ 217.14 | -2.2 % | $ 31.7 B | ||
|
AtriCure
ATRC
|
535 M | $ 28.48 | -1.93 % | $ 1.36 B | ||
|
Utah Medical Products
UTMD
|
9.04 M | $ 66.61 | -0.25 % | $ 216 M | ||
|
Harvard Bioscience
HBIO
|
86.6 M | $ 6.45 | -5.56 % | $ 286 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
West Pharmaceutical Services
WST
|
3.07 B | $ 292.13 | -3.33 % | $ 21.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.78 | -1.51 % | $ 2.35 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 10.98 | -0.99 % | $ 449 M | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 149.52 | -0.47 % | $ 43 B | ||
|
Nephros
NEPH
|
14.2 M | $ 3.32 | 2.79 % | $ 34.5 M | ||
|
OraSure Technologies
OSUR
|
115 M | $ 3.01 | - | $ 221 M | ||
|
Repligen Corporation
RGEN
|
632 M | $ 117.43 | -0.73 % | $ 6.54 M |